Spelling suggestions: "subject:"topoisomerase I inhibitor"" "subject:"topoisomerases I inhibitor""
1 |
Estudo do potencial anticÃncer de novos derivados acridÃnicos sintÃticos em modelos experimentais in vitro. / Study of the potential of new anticancer synthetic acridine derivatives in experimental models in vitro.Francisco Washington AraÃjo Barros 20 January 2010 (has links)
CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico / Acridinas sÃo molÃculas policÃclicas aromÃticas planares que possuem a capacidade de intercalar no DNA nuclear. Muitos dos seus representantes apresentam propriedades antibacterianas, antiparasitÃrias e antitumorais. O presente estudo avaliou o potencial citotÃxico de 22 novos compostos acridÃnicos em linhagens de cÃlulas tumorais humanas. Dentre esses, quatro compostos [5-(acridin-9-il-metileno)-3-(4-metil-benzil)-tiazolidina-2,4-diona, AC4; 5-(acridin-9-il-metileno)-3-(4-bromo-benzil)-tiazolidina-2,4-diona, AC7; 5-(acridin-9-il-metileno)-3-(4-cloro-benzil)-tiazolidina-2,4-diona, AC10; e 5-(acridin-9-il-metileno)-3-(4-flÃor-benzil)-tiazolidina-2,4-diona, AC23] foram ativos, especialmente em HCT-8 (cÃlon) e SF-296 (glioblastoma), com valores de CI50 variando de 2,3 a 5,3 Âg/mL. Os compostos apresentaram seletividade para cÃlulas tumorais, desde que nÃo inibiram (IC50 > 25 Âg/mL) a proliferaÃÃo de cÃlulas monocucleares de sangue perifÃrico humano (CMSPH), bem como, nÃo foram capazes de induzir dano ao DNA dessas cÃlulas. Nenhum dos compostos mostrou atividade hemolÃtica contra eritrÃcitos de camundongos (EC50 > 200 Âg/mL), o que sugere uma citotoxicidade por mecanismos mais especÃficos. A fim de determinar o mecanismo envolvido na citotoxicidade seletiva dos compostos, foi realizada uma seqÃÃncia de experimentos in vitro, usando a linhagem HCT-8 como modelo. As cÃlulas foram tratadas em diferentes concentraÃÃes dos compostos (2,5; 5 e 10 Âg/mL) por 12 e 24 horas. Todos os compostos foram capazes de reduzir a viabilidade (teste do azul de tripan) e a proliferaÃÃo (ensaio do BrdU) de cÃlulas HCT-8 apÃs o tratamento. A induÃÃo de apoptose pelos derivados acridÃnicos foi determinada por citometria de fluxo (integridade da membrana, fragmentaÃÃo do DNA internucleosomal e potencial transmembrÃnico) e por anÃlise morfolÃgica das alteraÃÃes celulares (brometo de etÃdeo/laranja de acridina e hematoxilina/eosina). A anÃlise por citometria de fluxo revelou que os compostos avaliados promoveram despolarizaÃÃo mitocondrial, o qual evidencia a ativaÃÃo da apoptose pela via intrÃnseca nas cÃlulas HCT-8. Na anÃlise do screening em 3 diferentes linhagens mutantes de Saccharomyces cerevisiae, foi observado que a linhagem Top1Δ (sem topoisomerase I) mostrou moderada resistÃncia aos compostos acridÃnicos testados na concentraÃÃo de 50 Âg/mL. AlÃm disso, as acridinas inibiram parcialmente o relaxamento do DNA por topoisomerase I, sugerindo que os compostos AC4, AC7, AC10, AC23 tem o potencial antiproliferativo, em parte, relacionado a inibiÃÃo da atividade catalÃtica desta enzima. Esses dados apontam o potencial anticÃncer dos compostos testados. / Acridines are planar aromatic polycyclic molecules that have the ability to progress in nuclear DNA. Many of its representatives have antibacterial, antiparasitic and antitumor. This study evaluated the cytotoxic potential of 22 new acridine compounds in strains of human tumor cells. Among these, four compounds [5-(acridin-9-yl-methilene)-3-(4-methyl-benzyl)-thiazolidine-2,4-dione, AC4; 5-(acridin-9-yl-methilene)-3-(4-bromine-benzyl)-thiazolidine-2,4-dione, AC7; 5-(acridin-9-yl-methilene)-3-(4-chloro-benzyl)-thiazolidine-2,4-dione, AC10; and 5-(acridin-9-yl-methilene)-3-(4-fluor-benzyl)-thiazolidine-2,4-dione, AC23] were active, especially in HCT-8 (colon) and SF-296 (glioblastoma), with IC50 values ranging from 2.3 to 5.3 mg / mL. The compounds were selective for tumor cells, provided they do not inhibit (IC50 > 25 Âg/mL) cell proliferation monocucleares human peripheral blood (CMSPH) and were not able to induce DNA damage to these cells. None of the compounds showed hemolytic activity against erythrocytes of mice (EC50 > 200 Âg/mL), suggesting a cytotoxicity by more specific mechanisms. In order to determine the mechanism involved in the selective cytotoxicity of compounds was carried out a sequence of in vitro experiments, using the line HCT-8 as a model. The cells were treated in different concentrations of compounds (2.5, 5 and 10 Âg/mL) for 12 and 24 hours. All compounds were able to reduce the viability test (trypan blue) and proliferation (BrdU assay) of HCT-8 cells after treatment. Induction of apoptosis by acridine derivatives was determined by flow cytometry (membrane integrity, DNA fragmentation and internucleosomal transmembrane potential) and morphological analysis of cellular changes (ethidium bromide/acridine orange, and hematoxylin-eosin). The analysis by flow cytometry showed that the compounds evaluated promoted mitochondrial depolarization, which shows the activation of apoptosis by intrinsic pathway in HCT-8 cells. In the analysis of screening in 3 different mutant strains of Saccharomyces cerevisiae, it was observed that the line Top1Δ (without topoisomerase I) showed resistance to acridine compounds tested at a concentration of 50 Âg/mL. In addition, the acridines partially inhibited the relaxation of DNA by topoisomerase I, suggesting that the compounds AC4, AC7, AC10, AC23 has the potential antiproliferative partly related to inhibition of catalytic activity of this enzyme. These data indicate the potential anticancer compounds tested.
|
2 |
Synthèse totale de deux nouveaux analogues de la camptothécine modifiés sur le cycle E / Total synthesis of two new analogs of camptothecin modified on E-ring.Devert, Marie 04 July 2011 (has links)
La 20(S)-camptothécine (CPT) est un alcaloïde pentacyclique doté d'une activité anticancéreuse remarquable, agissant comme inhibiteur de la topoisomérase I (topo I). Le problème majeur de ce composé (et de la plupart de ses dérivés) est la fragilité de son cycle E qui s'hydrolyse rapidement à pH physiologique pour conduire au carboxylate correspondant inactif. L'une des approches permettant de pallier ce problème d'hydrolyse consiste à modifier le cycle E. Ce travail de thèse porte sur la synthèse totale de deux nouveaux analogues de la CPT modifiés au niveau du cycle E. Chacune de ces synthèses fait appel à une cycloaddition [3+2] afin de préparer l'hydroxypyridone de départ (cycles C et D), à un réarrangement de Claisen permettant de mettre en place le cycle E et à une condensation de Friedländer pour installer le motif quinoléinique (cycles A et B). Le premier analogue synthétisé, la (±) 17 norcamptothécine (17-norCPT), possède une α-hydroxy γ-lactone à la place de l'α-hydroxy δ-lactone de la CPT. Ce composé a été obtenu en neuf étapes avec un rendement de 4,4% à partir de l'hydroxypyridone de départ. Le test d'inhibition de la topo I a été réalisé, mais cette molécule s'est révélée totalement inactive. Cependant, une étude de la cinétique d'hydrolyse de la 17-norCPT, réalisée par spectroscopie de fluorescence, a permis de montrer que cet analogue était très instable en milieu aqueux. Le second composé préparé est en fait un homologue de la 17 norCPT possédant un méthylène entre l'oxygène et le carbonyle de la lactone. Cette molécule, comportant un motif céto éther, est donc un isomère de la CPT. Elle a été obtenue par deux voies de synthèse différant l'une de l'autre par l'ordre des réactions mises en œuvre. Chacune de ces approches permet d'obtenir le composé souhaité en neuf étapes à partir de l'hydroxypyridone de départ, avec un rendement de 16% et 10% respectivement. Les tests biologiques sur le composé final sont actuellement en cours. / 20(S)-Camptothecin (CPT) is a pentacyclic alkaloid endowed with remarkable anticancer activity, acting as an inhibitor of topoisomerase I (topo I). The major problem with this compound (and many of its derivatives) is the fragility of its E-ring, which suffers rapid hydrolysis at physiological pH to yield the inactive corresponding carboxylate. One of the approaches to overcome this problem of hydrolysis consists in modifying the E-ring. This thesis focuses on the total synthesis of two new E-ring modified CPT analogs. Each of the syntheses involves a [3+2] cycloaddition to prepare the starting hydroxypyridone (rings C and D), a Claisen rearrangement to realize the E-ring, and a Friedländer condensation to install the quinoline system (rings A and B). The first analog synthesized, (±) 17 norcamptothecin (17-norCPT), has an α-hydroxy γ-lactone in place of the α-hydroxy δ-lactone of CPT. This compound has been obtained in nine steps with a yield of 4.4% from the starting hydroxypyridone. Unfortunately, though, this molecule has proved to be totally inactive in the topo I assay. A kinetic hydrolysis study of 17-norCPT, carried out by fluorescence spectroscopy, has demonstrated, however, that this analog is, in fact, unstable in aqueous media. The second compound prepared is a homolog of 17-norCPT with a methylene between the lactone oxygen and carbonyl, thus a CPT keto ether isomer. It has been obtained through two synthetic routes that differ from each other in the order of the steps. Each of the approaches yields the desired compound in nine steps from the starting hydroxypyridone, with yields of 16% and 10% for the two syntheses. Biological tests on the final compound are currently underway.
|
Page generated in 0.0522 seconds